Sozmen, MahmutDevrim, Alparslan KadirTunca, RecaiBayezit, MuratDag, SerpilEssiz, Dinc2020-06-252020-06-252014Sozmen M, Devrim AK, Tunca R, Bayezit M, Dag S, Essiz D. Protective effects of silymarin on fumonisin B1-induced hepatotoxicity in mice. J Vet Sci. 2014 Mar;15(1):51-60.1229-845X1976-555Xhttps://doi.org/10.4142/jvs.2014.15.1.51https://hdl.handle.net/20.500.12587/5850Essiz, Dinc/0000-0002-4759-7858The present study was conducted to investigate the effect of silymarin on experimental liver toxication induced by Fumonisin B-1 (FB1) in BALB/c mice. The mice were divided into six groups (n = 15). Group 1 served as the control. Group 2 was the silymarin control (100 mg/kg by gavage). Groups 3 and 4 were treated with FB1 (Group 3, 1.5 mg/kg FB1, intraperitoneally; and Group 4, 4.5 mg/kg FB1). Group 5 received FB1 (1.5 mg/kg) and silymarin (100 mg/kg), and Group 6 was given a higher dose of FB1 (4.5 mg/kg FB1) with silymarin (100 mg/kg). Silymarin treatment significantly decreased (p < 0.0001) the apoptotic rate. FB1 administration significantly increased (p < 0.0001) proliferating cell nuclear antigen and Ki-67 expression. Furthermore, FB1 elevated the levels of caspase-8 and tumor necrosis factor-alpha mediators while silymarin significantly reduced (p < 0.0001) the expression of these factors. Vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) expressions were significantly elevated in Group 4 (p < 0.0001). Silymarin administration alleviated increased VEGF and FGF-2 expression levels (p < 0.0001). In conclusion, silymarin ameliorated toxic liver damage caused by FB1 in BALB/c mice.eninfo:eu-repo/semantics/openAccesscaspase-8fumonisin B1fibroblast growth factor-2galectin-3silymarinArticle151516010.4142/jvs.2014.15.1.512-s2.0-8489637365224136215Q1WOS:000333503900006Q2